Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023

Rhea-AI Summary

Numinus Wellness (TSX: NUMI; OTCQX: NUMIF) announced Dr. Paul Thielking, Chief Science Officer, will join a Water Tower Research Fireside Chat on February 28, 2023, at 3:00 p.m. ET. The discussion will cover Numinus' clinical research activities at Cedar Clinical Research and the new research site in Phoenix, Arizona. This engagement highlights Numinus' commitment to advancing evidence-based psychedelic-assisted therapies aimed at improving mental health. Interested parties can register here.

VANCOUVER, BC, Feb. 24, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

The discussion will focus on Numinus' CRO activities conducted by Cedar Clinical Research (CCR); CCR growth and initiatives; and the new Phoenix, Arizona clinical research site.

For all investors and other persons interested in participating, please register here.

For more information about the event, or to schedule a one-on-one meeting with Numinus' management, please send an email to invest@numinus.com.

About Numinus

Numinus Wellness (TSX: NUMI; OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental healthcare and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-tuesday-february-28-2023-301755111.html

SOURCE Numinus Wellness Inc.

FAQ

What is the date and time of the Numinus Fireside Chat?

The Numinus Fireside Chat is scheduled for February 28, 2023, at 3:00 p.m. ET.

Who will participate in the Water Tower Research Fireside Chat?

Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in the chat.

What topics will be discussed during the Numinus Fireside Chat?

The discussion will focus on Numinus' CRO activities, including those at Cedar Clinical Research, and their new clinical research site in Phoenix, Arizona.

How can I register for the Numinus Fireside Chat?

Interested participants can register for the chat by clicking here.

What is Numinus Wellness's focus in mental health care?

Numinus Wellness focuses on innovative mental health care and the integration of safe, evidence-based psychedelic-assisted therapies.